Compare Quest Diagnostics Inc (DGX) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Las Vegas Sands Corp. — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Las Vegas Sands Corp. trades at $45.98 (market cap $29.44B). The key difference: Quest Diagnostics Inc and Las Vegas Sands Corp. are close in size by market cap, and Las Vegas Sands Corp. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| DGX | LVS | |
|---|---|---|
Market Cap | $26.21B | $29.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $69.49 |
52-Week Low | $173.49 | $44.78 |
Enterprise Value | $31.97B | $41.33B |
Dividend Yield | 1.45% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
LVS trades at $45.75, up 0.64% over the past 24 hours, with a bearish technical signal but strong fundamentals including a P/E of 17.62 and net income margin of 12.59%. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains robust cash flow from operations at $3.02 billion in 2025 and has announced a $0.30 dividend for H2 2026, reflecting financial stability.
The outlook for LVS is cautiously optimistic, supported by analyst consensus price target of $60.75 and 59% buy ratings. Key opportunities include revenue growth and ESG achievements, while risks involve high debt levels and competitive pressures in the gaming sector. Investors should weigh solid profitability against macroeconomic and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
